The "PassFirst®" manufactured and sold by PHC IVD is a compact, easy-to-move benchtop immunoluminescence measurement device used across a wide range of medical settings, from large hospitals to clinics. It adopts a chemiluminescence system combined with MAGTRATION*1 technology, providing rapid and high-quality testing. The "PassFirst®" is capable of measuring whole blood, plasma, and serum, making it a versatile diagnostic tool that can flexibly meet the diverse needs of medical environments. All the reagents required for measurement are stored in a single all-in-one cartridge, which also contains waste liquid, making handling exceptionally simple. Furthermore, measurement begins with just the push of a start button, and it can conduct six tests/batch and measure up to six items simultaneously in as little as 17 minutes. It is used in emergency departments and cardiology to test for conditions such as myocardial infarction, arrhythmia, and pulmonary embolism, and in obstetrics and gynecology for hormone level testing, among other applications.
In this renewed version of the "PassFirst®," the operation screen has been enlarged, and the graphical user interface (GUI)*2 has been redesigned to offer a more intuitive operation. A large opening door has been added to facilitate the smooth loading and unloading of reagents. Additionally, the device is now equipped with a built-in barcode reader and a status indicator lamp that visualizes the device's condition, further enhancing ease of use.
The "PassFirst®" celebrates its 20th anniversary since its launch and has contributed to rapid testing in medical settings in approximately 50 countries, including Japan, the U.S., Europe, Asia, the Middle East, and Latin America. PHC IVD will continue to support healthcare professionals by reducing their workload and delivering products and services that contribute to better healthcare.
Renewal Highlights of the Product
- Enlarged Operation Screen and GUI Update
The screen is now about twice the size of the previous model, significantly improving visibility and operability. The new GUI has been redesigned with simpler and more intuitive controls, improving the layout and user flow. - Large Opening Door
The newly introduced large opening door allows for smoother handling of reagents, reduces the risk of contact with the device's body, and enhances safety. - Integrated Barcode Reader
The built-in barcode reader enables easy scanning of specimen IDs with one hand, improving work efficiency. - Status Indicator Lamp
The status indicator lamp allows users to monitor the progress of tests even from a distance, reducing the risk of diagnostic delays. - Software Feature Additions
New features include a data search function that allows users to check the test result history from specimen or patient IDs and an automatic work log creation function, improving convenience.
About PHC Corporation's Diagnostic Division:
Founded in 1969, PHC Corporation is a Japanese healthcare company that operates globally under PHC Holdings Corporation (Stock Code: 6523, Tokyo Stock Exchange Prime). As a subsidiary of PHC Holdings, PHC Corporation's Diagnostic Division contributes to early disease detection and effective treatment of conditions such as diabetes and myocardial infarction (heart attack). The division develops, manufactures, and sells diagnostic and analytical devices such as blood glucose measurement systems and POCT (Point of Care Testing) devices, as well as in vitro diagnostic reagents.
About PHC Holdings Corporation (PHC Group
PHC Holdings Corporation (Stock Code: 6523, Tokyo Stock Exchange Prime) is a global healthcare company with a mission to create new value for all those wishing for better health and contribute to building a richer society. The company oversees a diverse group of subsidiaries, including PHC Corporation, Ascensia Diabetes Care Holdings, Epredia Holdings, LSI Medience Corporation, WeMeX Corporation, and Mediford Corporation. These subsidiaries focus on various business areas including diabetes management, healthcare solutions, diagnostics, and life sciences. They are involved in the development, manufacturing, sales, and service of medical devices and services across the globe. In fiscal year 2024, the PHC Group achieved consolidated sales revenue of ¥361.6 billion, serving customers in over 125 countries and regions.
